Iloprost
Pulmonary Fibrosis
ActelionSmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 89/ 100
Competitive context
16 Active assets in the Pulmonary Fibrosis cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
N-Acetyl-L-Cysteine Boehringer Ingelheim | Phase 3 | BB |
Nintedanib Boehringer Ingelheim | Phase 3 | BB |
Pirfenidone Boehringer Ingelheim | Phase 2 | BB |
Admilparant Bristol-Myers Squibb | Phase 3 | BB |
Sildenafil Alicia Gerke | Phase 3 | BB |
View all 38 →
Same molecule, other indications
Iloprost is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →